| All patients | Doxycycline | Placebo | |
| Subjects | 23 | 12 | 11 |
| Patient characteristics | |||
| Age years | 46.5±9.0 | 47.0±9.3 | 45.7±8.9 |
| Duration of disease year | 13.5±9.1 | 14.5±9.0 | 12.5±9.4 |
| Post-menopause | 8 | 4 | 4 |
| Pneumothorax# | 18 | 9 | 9 |
| Angiomyolipoma¶ | 14 | 6 | 8 |
| TSC-LAM | 1 | 0 | 1 |
| Supplemental oxygen use | 5 | 3 | 2 |
| Lung function % predicted | |||
| FEV1 | 58±23 | 52±25 | 64±19 |
| FVC | 95±22 | 97±26 | 92±18 |
| TLCO | 51±21 | 45±21 | 57±20 |
| TLC | 94±20 | 99±23 | 89±15 |
| Other parameters | |||
| Shuttle walk distance m | 573±286 | 560±284 | 586±301 |
| SGRQ total score | 35±4 | 36±6 | 33±6 |
| VEGF-D pg·mL−1 | 2540±1377 | 2347±1399 | 2751±1387 |
Data are presented as n or mean±sd. TSC: tuberous sclerosis complex; LAM: lymphangioleiomyomatosis; FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; TLCO: transfer factor of the lung for carbon monoxide; TLC: total lung capacity; SGRQ: St George’s Respiratory Questionnaire; VEGF-D: vascular endothelial growth factor D. #: number of patients having had at least one pneumothorax. ¶: number of patients with one or more angiomyolipoma at any time.